137 related articles for article (PubMed ID: 25770768)
21. Practical guide to the use of chemotherapy in castration resistant prostate cancer.
Petrylak DP
Can J Urol; 2014 Apr; 21(2 Supp 1):77-83. PubMed ID: 24775728
[TBL] [Abstract][Full Text] [Related]
22. [Fatal neutropenic enterocolitis in a patient with castration-resistant prostate cancer treated with first-line chemotherapy].
Kongsted P; Sheikh K; Mouritsen LS; Lindberg H; Sengeløv L
Ugeskr Laeger; 2015 Jan; 177(2A):24-5. PubMed ID: 25612951
[TBL] [Abstract][Full Text] [Related]
23. Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience.
Petrioli R; Roviello G; Fiaschi AI; Laera L; Miano ST; De Rubertis G; Barbanti G; Bianco V; Brozzetti S; Francini E
Med Oncol; 2015 Mar; 32(3):52. PubMed ID: 25636506
[TBL] [Abstract][Full Text] [Related]
24. Docetaxel-carboxymethylcellulose nanoparticles display enhanced anti-tumor activity in murine models of castration-resistant prostate cancer.
Hoang B; Ernsting MJ; Murakami M; Undzys E; Li SD
Int J Pharm; 2014 Aug; 471(1-2):224-33. PubMed ID: 24853460
[TBL] [Abstract][Full Text] [Related]
25. Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel.
Fernández O; Afonso J; Vázquez S; Campos B; Lázaro M; León L; Antón Aparicio LM
Anticancer Drugs; 2014 Mar; 25(3):237-43. PubMed ID: 24217332
[TBL] [Abstract][Full Text] [Related]
26. High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy.
Yao A; Sejima T; Iwamoto H; Masago T; Morizane S; Honda M; Takenaka A
Int J Urol; 2015 Sep; 22(9):827-33. PubMed ID: 26087772
[TBL] [Abstract][Full Text] [Related]
27. Co-introduction of a steroid with docetaxel chemotherapy for metastatic castration-resistant prostate cancer affects PSA flare.
Shiota M; Yokomizo A; Takeuchi A; Kiyoshima K; Inokuchi J; Tatsugami K; Shiga KI; Koga H; Yamaguchi A; Naito S; Eto M
BJU Int; 2016 Dec; 118(6):880-884. PubMed ID: 26991851
[TBL] [Abstract][Full Text] [Related]
28. Sequencing of Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices.
Sonpavde G; Bhor M; Hennessy D; Bhowmik D; Shen L; Nicacio L; Rembert D; Yap M; Schnadig I
Clin Genitourin Cancer; 2015 Aug; 13(4):309-318. PubMed ID: 25743206
[TBL] [Abstract][Full Text] [Related]
29. Prostate cancer: Cabazitaxel-a key therapeutic option in prostate cancer.
Jayaram A; Attard G
Nat Rev Urol; 2015 Jun; 12(6):312-3. PubMed ID: 26032550
[No Abstract] [Full Text] [Related]
30. Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients.
Caffo O; Lo Re G; Sava T; Buti S; Sacco C; Basso U; Zustovich F; Lodde M; Perin A; Facchini G; Veccia A; Maines F; Barile C; Fratino L; Gernone A; De Vivo R; Pappagallo GL; Galligioni E
Future Oncol; 2015; 11(6):965-73. PubMed ID: 25760977
[TBL] [Abstract][Full Text] [Related]
31. Prospective evaluation of [
Schwarzenböck SM; Eiber M; Kundt G; Retz M; Sakretz M; Kurth J; Treiber U; Nawroth R; Rummeny EJ; Gschwend JE; Schwaiger M; Thalgott M; Krause BJ
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2105-2113. PubMed ID: 27317482
[TBL] [Abstract][Full Text] [Related]
32. Castrate-resistant prostate cancer with peritoneal metastases treated with docetaxel-based chemotherapy.
Rizk R; Danse E; Aydin S; Tombal B; Machiels JP
Urol Int; 2014; 93(1):49-54. PubMed ID: 24296400
[TBL] [Abstract][Full Text] [Related]
33. Single-center experience with radium-223 in patients with castration-resistant prostate cancer and bone metastases.
Kapoor A; Wong NC; Wang Y; Mukherjee S; Hotte S; Dayes I; Lukka H
Asian J Androl; 2020; 22(4):437-438. PubMed ID: 31535625
[No Abstract] [Full Text] [Related]
34. Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.
Sonpavde G; Pond GR; Armstrong AJ; Galsky MD; Leopold L; Wood BA; Wang SL; Paolini J; Chen I; Chow-Maneval E; Mooney DJ; Lechuga M; Smith MR; Michaelson MD
BJU Int; 2014 Dec; 114(6b):E25-E31. PubMed ID: 24298897
[TBL] [Abstract][Full Text] [Related]
35. Treatment outcome of docetaxel plus prednisolone for metastatic castration-resistant prostate cancer in Korea.
Cho IC; Joung JY; Seo HK; Chung J; Park WS; Lee KH
J Cancer Res Ther; 2014; 10(2):251-7. PubMed ID: 25022374
[TBL] [Abstract][Full Text] [Related]
36. [Docetaxel and prostate cancer: Early but not too early].
Penel N; Ryckewaert T; Amela EY
Bull Cancer; 2015 Sep; 102(9):710-2. PubMed ID: 26235414
[No Abstract] [Full Text] [Related]
37. Quantitative Assessment of Early [
Harmon SA; Perk T; Lin C; Eickhoff J; Choyke PL; Dahut WL; Apolo AB; Humm JL; Larson SM; Morris MJ; Liu G; Jeraj R
J Clin Oncol; 2017 Aug; 35(24):2829-2837. PubMed ID: 28654366
[TBL] [Abstract][Full Text] [Related]
38. Docetaxel based chemotherapy in the treatment of patients with castration resistant prostate cancer.
Mangir N; Türkeri L
Actas Urol Esp; 2014 Oct; 38(8):515-22. PubMed ID: 24646918
[TBL] [Abstract][Full Text] [Related]
39. [Docetaxel chemotherapy against CRPC].
Nagao K; Matsuyama H
Nihon Rinsho; 2016 May; 74 Suppl 3():619-23. PubMed ID: 27344805
[No Abstract] [Full Text] [Related]
40. Aged patients with metastatic castration resistant prostate cancer: Should we treat with chemotherapy?
Climent MÁ; Torregrosa MD; Vázquez S; Gironés R; Arranz JA
Cancer Treat Rev; 2017 Apr; 55():173-180. PubMed ID: 28411479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]